Russell Investments Group, Ltd. Avenue Therapeutics, Inc. Transaction History

Russell Investments Group, Ltd.

  • $60.3 Billion
  • Q2 2024

Shares

2 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q4 2020

Feb 08, 2021
SELL
$2.95 - $11.04 $47,990 - $179,598
-16,268 Closed
0 $0
Q3 2020

Nov 09, 2020
BUY
$9.37 - $12.06 $152,431 - $196,192
16,268 New
16,268 $176,000

About AVENUE THERAPEUTICS, INC.

ATXI Quotes by TradingView
  • Ticker ATXI
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 4,127,720
  • Market Cap $9.25M
  • Description
  • Avenue Therapeutics, Inc., a specialty pharmaceutical company, develops and commercializes products primarily for use in the acute/intensive care hospital setting. Its product candidate is intravenous Tramadol, a synthetic dual-acting opioid, which is in Phase III clinical trials for the treatment of post-operative acute pain. The company was in...
More about ATXI
Track This Portfolio

Track Russell Investments Group, Ltd. Portfolio

Follow Russell Investments Group, Ltd. and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Russell Investments Group, Ltd., based on Form 13F filings with the SEC.

News

Stay updated on Russell Investments Group, Ltd. with notifications on news.

Choose your preferred platform and Sign Up 👇 Telegram Email